PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DX21FZ8ZK4554991786!rituxan 500 MG 50 ML VIAL 50ml — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DX15D9353. PoP ended Oct 19, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Dms Pharmaceutical Group Inc

Recipient

Oct 19, 2021

PoP end

$130K

Obligated

$130K

Potential

325411

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal

Contract numberSPE2DX21FZ8ZK

Also listed asSPE2DX15D9353-SPE2DX21FZ8ZK

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentDms Pharmaceutical Group Inc

CAGE1UNB0

UEIPX72BSBQTKJ3

NAICS325411

No full NAICS 325411 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DX15D9353

Place of performancePARK RIDGE IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 27, 2021

PoP end (current)Oct 19, 2021

Obligated$130K

Current value$130K

Potential value$130K

4554991786!RITUXAN 500 MG/50 ML VIAL 50ML is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $130K ($130K obligated). Current period of performance ends Oct 19, 2021. Place of performance: PARK RIDGE IL.

4554991786!RITUXAN 500 MG/50 ML VIAL 50ML

Recompete timing

Public

● Past PoP end (1767 days ago)

Current PoP ended Oct 19, 2021 (1767 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies

Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D026F0120

8511978882!OTHER MEDICAL

$248K

Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DX21FZ8ZK?

SPE2DX21FZ8ZK (4554991786!rituxan 500 MG 50 ML VIAL 50ml) is a Dla Troop Support award with a potential value of $130K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DX21FZ8ZK?

Dla Troop Support awarded SPE2DX21FZ8ZK to Dms Pharmaceutical Group Inc (potential $130K).

Who is the incumbent on SPE2DX21FZ8ZK?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Oct 19, 2021.

When does Dms Pharmaceutical Group Inc’s SPE2DX21FZ8ZK come up for recompete?

SCOUT tracks a period-of-performance end of Oct 19, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 1, 2026 · refreshed monthlyLatest procurement action Sep 27, 2021